Bristol-Myers Squibb/Pfizer Alliance – Advancing Management and Care in Atrial Fibrillation and Venous Thromboembolism RFP
Academic Unit: inquire with unit
Memorial Deadline: Thursday 28th, July 2022
External Deadline: Wednesday 3rd, August 2022
Pfizer and Bristol-Myers Squibb (BMS) are collaborating to provide grant support for continuing professional education in the areas of atrial fibrillation and venous thromboembolism. We are committed to supporting innovative, independent medical education for healthcare professionals.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer and BMS must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: June 28, 2022
Geographic Scope: Global
Clinical Area: Atrial Fibrillation/Venous Thromboembolism
Application Due Date: August 3, 2022
Specific Area of Interest: Projects that will be considered for support will focus on improving the care of patients by addressing knowledge gaps in Atrial Fibrillation and stroke prevention or Venous Thromboembolism or both areas.